AnaptysBio, Inc. ANAB Royalty Management Company — Noncash Advance Future Royalties Interest Expense

Other segment segments

Similar metrics at other companies

RARENon Cash Interest Expense On Liability Related To Sale Of Future Royalties

$21M+50.0%

RARENon Cash Interest Expense On Liability Related To Sale Of Future Royalties

$21M+50.0%

BCRXNon-cash interest expense on royalty financing obligations

$13.29M-1.6%

BBIONoncash interest expense on deferred royalty obligations

$39.87M+66.0%

PTCTNoncash Interest Expense Liability Related To Sale Of Future Royalties

$65.7M+32.3%

BCRXNon-cash interest expense on royalty financing obligations

$13.29M-1.6%

Questions, answered.

What is AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense?

AnaptysBio, Inc. (ANAB) reported royalty management company — noncash advance future royalties interest expense of $20.86M in Q1 2026.

How has AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense changed year-over-year?

AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense increased by 15.5% year-over-year, from $18.06M to $20.86M.

What does royalty management company — noncash advance future royalties interest expense mean?

This metric represents the non-cash interest expense associated with financing arrangements or advances received against future royalty streams. It highlights the cost of capital tied to monetizing future cash flows upfront.